grey market peptides retatrutide Retatrutide, an experimental weight-loss drug, has not been approved by the FDA. But, doctors and nurse practitioners in clinics across the country are prescribing it anyway, a CBS News investigation People Are Already Taking This

Yet we found surprising gaps in transparency

While promising, Ozempic is not yet approved for treating alcohol use disorder, and more studies are needed

Cardiologists treating patients with atherosclerotic cardiovascular disease are increasingly initiating semaglutide as a cardiovascular risk modifier, adding an estimated 4.8 million new commercial GLP-1 patients annually

Modern sedentary activities promote overconsumption of food in our current obesogenic environment

This means semaglutide users often add more water (2-3mL) to keep lower doses measurable, while retatrutide users at higher doses may prefer less water (1mL) to keep injection volumes manageable

However, it is not possible to confirm it is the strongest weight loss medicine until more research and comparisons with approved treatments are available